Biotech Values

[10nisman]

MNTA’s $5M milestone for FDA approval of generic Lovenox is separate from the $163M of remaining potential milestones from the 2006 NVS-MNTA collaboration. The $163M pertains to Lovenox in the EU, specifically, and to Copaxone.

Dew, any guestimate of how much of the remaining $163M of potential milestones pertains to Copaxone and how much MNTA may receive upon FDA Approval?

Additionally, NVS will pay MNTA an undisclosed amount on each of five anniversaries of the 23-Jul-2010 US Lovenox launch (probably the first, second, third, fourth, and fifth anniversaries, although the schedule might be different). Note that the anniversary milestones for the US Lovenox launch are separate from the $163M MNTA can potentially receive from NVS for milestones relating to Lovenox in the EU, specifically, and to the Copaxone program.

Any guestimate on the amount to be received on the five anniversary dates? Do you think the amount to be received is contingent on whether another generic is approved?

Thanks,
10nis